Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutions's Other Operating Expense for the
three
months ended in Jun. 2026 was €8.4 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €33.0 Mil.
Emergent BioSolutions's quarterly Other Operating Expense
declined
from Dec. 2025 (€9.7 Mil) to Mar. 2026 (€8.7 Mil) and
declined
from Mar. 2026 (€8.7 Mil) to Jun. 2026 (€8.4 Mil).
Emergent BioSolutions's annual Other Operating Expense
declined
from Dec. 2023 (€36.0 Mil) to Dec. 2024 (€33.5 Mil) and
declined
from Dec. 2024 (€33.5 Mil) to Dec. 2025 (€23.4 Mil).
Emergent BioSolutions Other Operating Expense Related Terms
Emergent BioSolutions Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €33.0 Mil mean?
Emergent BioSolutions (FRA:ER4) has a Other Operating Expense of €33.0 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Other Operating Expense too high?
Emergent BioSolutions' current Other Operating Expense is €33.0 Mil. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Other Operating Expense compare to EOLS and ELTP?
Emergent BioSolutions' Other Operating Expense of €33.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Other Operating Expense is €33.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (FRA:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €6.54 — trading 57.5% above its estimated fair value. The current Other Operating Expense is €33.0 Mil. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Emergent BioSolutions (FRA:ER4), the current Other Operating Expense is €33.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €6.54 is trading 57.5% above its estimated GF Value™ of €4.15.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for FRA:ER4:
Other Operating Expense: €33.0 Mil
GF Value™: €4.15 vs. price of €6.54 (57.5% above fair value)
No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score
Get the complete analysis for FRA:ER4
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ER4 has been successfully added to your 
